Active substance
Results for the substance niraparib
1 result
About this active substance
Niraparib is a PARP (poly-ADP-ribose polymerase) enzyme inhibitor primarily used for the treatment of recurrent ovarian cancer. This medication is indicated for patients who have responded to platinum-based chemotherapy, serving as a maintenance therapy. Niraparib works by inhibiting DNA repair in cancer cells, leading to their death.
This drug is usually administered orally, once daily, with the dose adjusted based on the patient's weight and individual tolerance. Common side effects include nausea, fatigue, anemia, and constipation. Regular monitoring is essential to assess potential adverse reactions.
Niraparib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Additionally, its use during pregnancy and breastfeeding is not recommended, as it may harm the fetus or infant.
This medication represents an important option for patients with ovarian cancer, offering a chance to prolong survival without disease progression. It is crucial that treatment is administered under the supervision of a specialist physician.
This drug is usually administered orally, once daily, with the dose adjusted based on the patient's weight and individual tolerance. Common side effects include nausea, fatigue, anemia, and constipation. Regular monitoring is essential to assess potential adverse reactions.
Niraparib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Additionally, its use during pregnancy and breastfeeding is not recommended, as it may harm the fetus or infant.
This medication represents an important option for patients with ovarian cancer, offering a chance to prolong survival without disease progression. It is crucial that treatment is administered under the supervision of a specialist physician.